Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIV

Animals Receptors, IgG / immunology Simian Acquired Immunodeficiency Syndrome / immunology HIV-1 / immunology Simian Immunodeficiency Virus / immunology Macaca mulatta Antibodies, Neutralizing / immunology HIV Antibodies / immunology Antibodies, Monoclonal / immunology Lymph Nodes / immunology CD8-Positive T-Lymphocytes / immunology Antibody Affinity / immunology NF-kappa B / metabolism Humans HIV Infections / immunology Killer Cells, Natural / immunology Broadly Neutralizing Antibodies / immunology

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
29 Aug 2024
Historique:
received: 05 03 2024
accepted: 20 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 28 8 2024
Statut: epublish

Résumé

Anti-HIV-1 broadly neutralizing antibodies (bNAbs) have the dual potential of mediating virus neutralization and antiviral effector functions through their Fab and Fc domains, respectively. So far, bNAbs with enhanced Fc effector functions in vitro have only been tested in NHPs during chronic simian-HIV (SHIV) infection. Here, we investigate the effects of administering in acute SHIV

Identifiants

DOI: 10.1038/s41467-024-51848-y PMID: 39198422
pubmed: 39198422
doi: 10.1038/s41467-024-51848-y
pii: 10.1038/s41467-024-51848-y
doi:

Substances chimiques

Receptors, IgG 0
Antibodies, Neutralizing 0
HIV Antibodies 0
Antibodies, Monoclonal 0
NF-kappa B 0
Broadly Neutralizing Antibodies 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7461

Subventions

Organisme : Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
ID : OPP1147555
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : 75N91019D00024/HHSN261201500003I

Informations de copyright

© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Références

World Health Organization Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization: Geneva, 2021.
Arts, E. J. & Hazuda, D. J. HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. Med. 2, a007161 (2012).
pubmed: 22474613 pmcid: 3312400 doi: 10.1101/cshperspect.a007161
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
pubmed: 9360927 doi: 10.1126/science.278.5341.1295
Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).
pubmed: 9360926 doi: 10.1126/science.278.5341.1291
Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193–13197 (1997).
pubmed: 9371822 pmcid: 24285 doi: 10.1073/pnas.94.24.13193
Chun, T. W., Davey, R. T. Jr., Engel, D., Lane, H. C. & Fauci, A. S. Re-emergence of HIV after stopping therapy. Nature 401, 874–875 (1999).
pubmed: 10553903 doi: 10.1038/44755
Davey, R. T. Jr. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96, 15109–15114 (1999).
pubmed: 10611346 pmcid: 24781 doi: 10.1073/pnas.96.26.15109
Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636–640 (2009).
pubmed: 19287373 doi: 10.1038/nature07930
Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010).
pubmed: 20616233 pmcid: 2965066 doi: 10.1126/science.1187659
Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633–1637 (2011).
pubmed: 21764753 pmcid: 3351836 doi: 10.1126/science.1207227
Bonsignori, M. et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86, 4688–4692 (2012).
pubmed: 22301150 pmcid: 3318651 doi: 10.1128/JVI.07163-11
Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009).
pubmed: 19729618 pmcid: 3335270 doi: 10.1126/science.1178746
Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55–62 (2014).
pubmed: 24590074 pmcid: 4395007 doi: 10.1038/nature13036
Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 111, 17624–17629 (2014).
pubmed: 25422458 pmcid: 4267403 doi: 10.1073/pnas.1415789111
Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 109, E3268–E3277 (2012).
pubmed: 23115339 pmcid: 3511153 doi: 10.1073/pnas.1217207109
Sok, D. et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med. 6, 236ra263 (2014).
doi: 10.1126/scitranslmed.3008104
Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011).
pubmed: 21849977 pmcid: 3393110 doi: 10.1038/nature10373
Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406–412 (2012).
pubmed: 23151583 pmcid: 4854285 doi: 10.1038/nature11544
Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277–280 (2013).
pubmed: 24172896 pmcid: 4133787 doi: 10.1038/nature12746
Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224–228 (2013).
pubmed: 24172905 pmcid: 4017780 doi: 10.1038/nature12744
Julg, B. et al. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. J. Virol. 91, e00498–17 (2017).
Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487–491 (2015).
pubmed: 25855300 pmcid: 4890714 doi: 10.1038/nature14411
Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).
pubmed: 26702094 doi: 10.1126/scitranslmed.aad5752
Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185–191 (2017).
pubmed: 28092665 pmcid: 5467219 doi: 10.1038/nm.4268
Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701–1707 (2018).
pubmed: 30258217 pmcid: 6221973 doi: 10.1038/s41591-018-0186-4
Hessell, A. J. et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat. Med. 22, 362–368 (2016).
pubmed: 26998834 pmcid: 4983100 doi: 10.1038/nm.4063
Shapiro, M. B. et al. Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. Nat. Commun. 11, 70 (2020).
pubmed: 31911610 pmcid: 6946664 doi: 10.1038/s41467-019-13972-y
Bolton, D. L. et al. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. J. Virol. 90, 1321–1332 (2016).
pubmed: 26581981 pmcid: 4719604 doi: 10.1128/JVI.02454-15
Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559–563 (2017).
pubmed: 28289286 pmcid: 5458531 doi: 10.1038/nature21435
Platzer, B., Stout, M. & Fiebiger, E. Antigen cross-presentation of immune complexes. Front Immunol. 5, 140 (2014).
pubmed: 24744762 pmcid: 3978348 doi: 10.3389/fimmu.2014.00140
Pelegrin, M., Naranjo-Gomez, M. & Piechaczyk, M. Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents? Trends Microbiol. 23, 653–665 (2015).
pubmed: 26433697 pmcid: 7127033 doi: 10.1016/j.tim.2015.07.005
Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989–999 (2014).
pubmed: 25131989 pmcid: 4163911 doi: 10.1016/j.cell.2014.07.043
Bournazos, S. et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243–1253 (2014).
pubmed: 25215485 pmcid: 4167398 doi: 10.1016/j.cell.2014.08.023
Lu, C. L. et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001–1004 (2016).
pubmed: 27199430 pmcid: 5126967 doi: 10.1126/science.aaf1279
Flerin, N. C. et al. Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs. J. Virol. 93, e02051–18 (2019).
Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101–104 (2007).
pubmed: 17805298 doi: 10.1038/nature06106
Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951–954 (2009).
pubmed: 19525965 pmcid: 4334439 doi: 10.1038/nm.1974
Moldt, B. et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86, 6189–6196 (2012).
pubmed: 22457527 pmcid: 3372207 doi: 10.1128/JVI.00491-12
Parsons, M. S. et al. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. J. Clin. Invest. 129, 182–191 (2019).
pubmed: 30475230 doi: 10.1172/JCI122466
Asokan, M. et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc. Natl. Acad. Sci. USA 117, 18754–18763 (2020).
pubmed: 32690707 pmcid: 7414046 doi: 10.1073/pnas.2008236117
Wang, P. et al. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. Proc. Natl. Acad. Sci. USA 117, 18002–18009 (2020).
pubmed: 32665438 pmcid: 7395461 doi: 10.1073/pnas.2008190117
Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103, 4005–4010 (2006).
pubmed: 16537476 pmcid: 1389705 doi: 10.1073/pnas.0508123103
Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669–12682 (2014).
pubmed: 25142607 pmcid: 4248941 doi: 10.1128/JVI.02213-14
Julg, B. et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci. Transl. Med. 9, eaao4235 (2017).
pubmed: 28931655 pmcid: 5747528 doi: 10.1126/scitranslmed.aao4235
Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157–159 (2010).
pubmed: 20081867 pmcid: 2855492 doi: 10.1038/nbt.1601
Ko, S. H. et al. High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19. PLoS Pathog. 17, e1009431 (2021).
pubmed: 33831133 pmcid: 8031304 doi: 10.1371/journal.ppat.1009431
Julien, J. P. et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 9, e1003342 (2013).
pubmed: 23658524 pmcid: 3642082 doi: 10.1371/journal.ppat.1003342
Crowley, A. R. & Ackerman, M. E. Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function. Front Immunol. 10, 697 (2019).
pubmed: 31024542 pmcid: 6463756 doi: 10.3389/fimmu.2019.00697
Dias, J. et al. Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. J. Clin. Invest. 131, e151632 (2021).
pubmed: 34623326 pmcid: 8409578 doi: 10.1172/JCI151632
Hsu, D. C. et al. TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. PLoS Pathog. 17, e1009339 (2021).
pubmed: 33600506 pmcid: 7924766 doi: 10.1371/journal.ppat.1009339
Gaudinski, M. R. et al. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV 6, e667–e679 (2019).
pubmed: 31473167 pmcid: 11100866 doi: 10.1016/S2352-3018(19)30181-X
Ledgerwood, J. E. et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289–301 (2015).
pubmed: 26332605 pmcid: 4636891 doi: 10.1111/cei.12692
Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).
pubmed: 29364886 pmcid: 5783347 doi: 10.1371/journal.pmed.1002493
Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718–1724 (2021).
pubmed: 34621054 pmcid: 8516645 doi: 10.1038/s41591-021-01509-0
Shingai, M. et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc. Natl. Acad. Sci. USA 109, 19769–19774 (2012).
pubmed: 23129652 pmcid: 3511737 doi: 10.1073/pnas.1217443109
Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061–2074 (2014).
pubmed: 25155019 pmcid: 4172223 doi: 10.1084/jem.20132494
Nguyen, D. C., Scinicariello, F. & Attanasio, R. Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics 63, 351–362 (2011).
pubmed: 21327607 doi: 10.1007/s00251-011-0514-z
Chan, Y. N. et al. IgG Binding Characteristics of Rhesus Macaque FcgammaR. J. Immunol. 197, 2936–2947 (2016).
pubmed: 27559046 doi: 10.4049/jimmunol.1502252
Li, H. et al. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc. Natl. Acad. Sci. USA 113, E3413–E3422 (2016).
pubmed: 27247400 pmcid: 4914158
Hansen, S. G. et al. Addendum: Immune clearance of highly pathogenic SIV infection. Nature 547, 123–124 (2017).
pubmed: 28636599 doi: 10.1038/nature22984
Zhou, T. et al. Transplanting supersites of HIV-1 vulnerability. PLoS One 9, e99881 (2014).
pubmed: 24992528 pmcid: 4084637 doi: 10.1371/journal.pone.0099881
Boritz, E. A. et al. Multiple Origins of Virus Persistence during Natural Control of HIV Infection. Cell 166, 1004–1015 (2016).
pubmed: 27453467 pmcid: 4983216 doi: 10.1016/j.cell.2016.06.039
Hepler, N. L. et al. An Improved Circular Consensus Algorithm with an Application to Detect HIV-1 Drug-Resistance Associated Mutations (DRAMs). An Improved Circular Consensus Algorithm with an Application to Detect HIV-1 Drug-Resistance Associated Mutations (DRAMs). Conference on Advances in Genome Biology and Technology; 2016.
Smith, T., Heger, A. & Sudbery, I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res. 27, 491–499 (2017).
pubmed: 28100584 pmcid: 5340976 doi: 10.1101/gr.209601.116
Yamamoto, T. et al. Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection. Sci. Transl. Med. 7, 298ra120 (2015).
pubmed: 26223303 doi: 10.1126/scitranslmed.aab3964
Cowell, R. L., Dorsey, K. E. & Meinkoth, J. H. Lymph node cytology. Vet. Clin. North Am. Small Anim. Pr. 33, 47–67, v (2003).
doi: 10.1016/S0195-5616(02)00055-4
Tasnim, H. et al. Quantitative Measurement of Naïve T Cell Association With Dendritic Cells, FRCs, and Blood Vessels in Lymph Nodes. Front Immunol. 9, 1571 (2018).
pubmed: 30093900 pmcid: 6070610 doi: 10.3389/fimmu.2018.01571
Kuznetsov, Y. G., Victoria, J. G., Robinson, W. E. Jr. & McPherson, A. Atomic force microscopy investigation of human immunodeficiency virus (HIV) and HIV-infected lymphocytes. J. Virol. 77, 11896–11909 (2003).
pubmed: 14581526 pmcid: 254268 doi: 10.1128/JVI.77.22.11896-11909.2003
Radecki, P., Ko, S. H., Lucas, M. & Boritz, E. niaid/UMI-pacbio-pipeline: v1 with SHIV (1-dc6ef5c). 2024 [cited]Available from: https://doi.org/10.5281/zenodo.12825013 .
Talla, A., Pelletier, A., Fourati, S. & Al-Shakhshir, H. sekalylab/mRNASeq: Zenodo release (v1.0.0). 2024 [cited]Available from: https://doi.org/10.5281/zenodo.12802634 .
Fourati, S. sekalylab/joana: Zenodo release (v1.0.0). 2024 [cited]Available from: https://doi.org/10.5281/zenodo.12801249 .

Auteurs

Joana Dias (J)

Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-1187-8770

Giulia Fabozzi (G)

Tissue Analysis Core, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Slim Fourati (S)

Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA, USA.
ORCID: 0000-0001-6609-7587

Xuejun Chen (X)

Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0001-9192-0440

Cuiping Liu (C)

Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0001-8390-1047

David R Ambrozak (DR)

Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Amy Ransier (A)

Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Farida Laboune (F)

Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Jianfei Hu (J)

Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Wei Shi (W)

Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Kylie March (K)

Tissue Analysis Core, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Anna A Maximova (AA)

Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Stephen D Schmidt (SD)

Humoral Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Jakob Samsel (J)

Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Institute for Biomedical Sciences, George Washington University, Washington, D.C., USA.

Chloe A Talana (CA)

Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-0313-8502

Keenan Ernste (K)

Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-2988-6429

Sung Hee Ko (SH)

Virus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-4678-7449

Margaret E Lucas (ME)

Virus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0009-0003-4147-1896

Pierce E Radecki (PE)

Virus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-1103-5327

Kristin L Boswell (KL)

Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Yoshiaki Nishimura (Y)

Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0003-1347-2368

John-Paul Todd (JP)

Translational Research Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Malcolm A Martin (MA)

Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-6845-9905

Constantinos Petrovas (C)

Tissue Analysis Core, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Eli A Boritz (EA)

Virus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Nicole A Doria-Rose (NA)

Humoral Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0002-5731-3054

Daniel C Douek (DC)

Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
ORCID: 0000-0001-5575-8634

Rafick-Pierre Sékaly (RP)

Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA, USA.
ORCID: 0000-0002-7816-4828

Jeffrey D Lifson (JD)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Mangaiarkarasi Asokan (M)

Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Lucio Gama (L)

Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

John R Mascola (JR)

ModeX Therapeutics, Weston, MA, USA.

Amarendra Pegu (A)

Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Richard A Koup (RA)

Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. rkoup@mail.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteur Fc › Récepteurs du fragment Fc des IgG › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Maladies de l'animal › Maladies des primates › Maladies des singes › Syndrome d'immunodéficience acquise du singe › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Rétrovirus simiens › Virus de l'immunodéficience simienne › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Macaca mulatta › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Anticorps antideltarétrovirus › Anticorps anti-VIH › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système lymphatique › Tissu lymphoïde › Noeuds lymphatiques › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Phénomènes du système immunitaire › Réaction antigène-anticorps › Affinité des anticorps › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteur de transcription NF-kappa B › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Cellules tueuses naturelles › Administration of anti-HIV-1 broadly...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Anticorps neutralisants à large spectre › Administration of anti-HIV-1 broadly...